heterogeneous nuclear ribonucleoprotein L pseudogene 2Genealiases: []
Q-omics provides the consensus-scored HNRNPLP2 profile across patient tissues and cancer cell-line models. HNRNPLP2 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, HNRNPLP2 is differentially expressed in 15, with the highest sampling consensus in COAD. Additionally, HNRNPLP2 RNA expression shows 18,674 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, COAD, and ACC as cancer lineages where HNRNPLP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HNRNPLP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HNRNPLP2 survival associations across molecular data types. HNRNPLP2 RNA expression shows survival associations in the most cancer types (26). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HNRNPLP2 RNA expression–survival associations across cancer types. High HNRNPLP2 expression shows unfavorable associations in KICH, LIHC and BLCA, but favorable associations in UVM, THYM and LGG. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for HNRNPLP2 RNA expression.
This table summarizes HNRNPLP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for HNRNPLP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HNRNPLP2 shows lower tumor expression in THCA and BRCA and higher tumor expression in COAD, HNSC, KIRP and LIHC. The COAD box plot shows higher HNRNPLP2 RNA expression in tumor versus normal tissue (log2 FC = +0.798, t-test p < 0.001).
This table shows molecular features associated with HNRNPLP2 in patient tissues and cancer cell lines. In patient samples, HNRNPLP2 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
